 Patent Application Title |
Patent App Num. |
Date |
| Hypoxia induced mitogenic factor | 20110008349 | 20110113 |
| We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
... |
| Treating patients with subarachnoid hemorrhage | 20110003012 | 20110106 |
| A method for attenuating vasoconstriction in a patient with subarachnoid hemorrhage by administering to the patient a therapeutically effective amount of a compound which mediates an increase of bioactive nitric oxide in blood or tissue in the subarachnoid space to cause vasodilation in cerebral, carotid and basilar arteries after the administration of the compound, and wherein the administration of the compound does not reduce mean arterial blood pressure by more than 10%.
... |
| Monitoring cardiovascular conditions using signal transit times | 20100331708 | 20101230 |
| Methods for monitoring cardiovascular conditions, i.e., hyperdynamic circulation, vasodilation, vasoconstriction, or central-to-peripheral arterial pressure decoupling conditions are described. These methods involve measuring a central signal proportional to or a function of the subject's heart activity and a peripheral signal proportional to or a function of a signal related to the central signal. Then calculating a time difference between features in the central and peripheral signals representing the same heart event. The cardiovascular condition is indicated if the time difference is greater or lower than a threshold value, if the time difference is greater or lower than a threshold value over a specified period of time, or if there is a significant statistical change in the times over the specified time period. These methods can alert a... |
| Compositions and methods for modulation of vascular structure and/or function | 20100323986 | 20101223 |
| The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a β-1-4 conformation.
... |
| Novel bronchodilating alpha, beta-unsaturated isoquinoline amides | 20100256101 | 20101007 |
| The invention relates to novel compounds having the general formula (I), and which compounds are useful to manufacture a medicament to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma, and vasoconstriction, e.g. hypertension.
... |
Subscribe to updates on this page: Vasocon RSS  |
| New use for cannabinoid-containing plant extracts | 20100249223 | 20100930 |
| The present invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of diseases or conditions that are alleviated by blockade of one or more types of TRP channel. Preferably the subset of TRP channel that is blockaded is the TRPA channel. More preferably the TRPA channel is the TRPA1 channel. Preferably the diseases or conditions to be prevented or treated include: neuropathic pain, inflammation or vasoconstriction. Alternatively the TRP channel that is blockaded is the TRPM channel. More preferably the TRPM channel is the TRPM8 channel. Preferably the diseases or conditions to be prevented or treated are cancer. More preferably the cancers to be treated include: cancer of the prostate, cancer of the breast, cancer of the colon, cancer of the... |
| Methods for the diagnosis and for the treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists | 20100209433 | 20100819 |
| Submitted herewith is a sequence listing in computer readable form for entry into the present application. Also enclosed is a pdf copy of the as-filed sequence listing and a Checker Program report indicating that the text file of the sequence listing contains no errors.
... |
| Indications for local transport of anaesthetic agents by electrotransport devices | 20100191216 | 20100729 |
| The use of an iontophoresis electrode assembly for delivery of a drug formulation is described. The drug formulation includes an anaesthetic and a vasoconstrictor. It is administered to a patient prior to a procedure to produce clinically acceptable depth and duration of dermal anaesthesia at the portion of skin to subject to a painful procedure or to reduce or eliminate pain. The procedure is one selected from the group consisting of venipuncture, IV cannulation, needle aspirations, body piercings, blood donations, electrolysis, tattoo removal, tattoo application, injections, dermabrasion, skin peeling, high velocity particle ablation, pace maker implantation, pace maker replacement, epidural puncture, lumbar puncture, regional nerve blocks, skin harvesting, small skin incisions, skin biopsies, circumcisions or excisions. The iontophoresis electrode assembly may also be used to reduce... |
| Methods of nasopharyngeal cooling for augmenting coronary perfusion pressure | 20100174278 | 20100708 |
| A method for improving the success of resuscitation efforts following cardiac arrest is provided. Return of spontaneous circulation (ROSC) rates following cardiac arrest is directly related to the coronary perfusion pressure during cardiopulmonary resuscitation (CPR). Selective cooling of the nasal cavity, nasopharynx, oral cavity, oropharynx, retrotonsillar space, mouth, neck face, and/or throat of a patient suffering from cardiac arrest, significantly increases the coronary perfusion pressure which improves ROSC rates. Cooling may be initiated before or during resuscitation efforts including chest compressions, defibrillation and/or administering a vasoconstrictor.
... |
| Composition for treatment of common cold | 20100093783 | 20100415 |
| New stable compositions comprising the combination of a topically active vasoconstrictor and a topically active anticholinergic drug are disclosed. Preferably, the composition comprises ipratropium or a salt thereof in combination with xylometazoline hydrochloride and a salt thereof. Upon topically administering such compositions to a nasal mucosa in individuals suffering from the common cold the symptoms of rhinorrhea are significantly reduced.
... |
| Polyanhydrides with therapeutically useful degradation products | 20100074937 | 20100325 |
| is disclosed, wherein Ar and R are selected so that the aromatic polyanhydride hydrolyzes to form a therapeutic salicylate, another non-steroidal anti-inflammatory, an antifibrotic aminobenzoate, or a vasoconstricting phenylethanolamine. Implantable medical devices, such as scaffolding implants for tissue reconstruction, drug delivery systems prepared from the aromatic polyanhydrides, as well as therapeutic dosage forms and treatment methods are also disclosed.
... |
| Endothelin receptor antagonists | 20100063076 | 20100311 |
| This invention relates to novel endothelin receptor antagonists, derivatives, acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by compounds that block the endothelin signaling pathway that leads to vasoconstriction and in particular those diseases or conditions beneficially treated by endothelin receptor antagonists.
... |
| Composition and method for treating hemorrhoids and/or anorectal disorders | 20100055185 | 20100304 |
| The invention provides an oil-in-water emulsion useful in the treatment of anorectal disorders comprising a local anesthetic, vasoconstrictor, glycerin and water, and method of preparation of the emulsion and a method for treating hemorrhoids using the composition of the invention.
... |
Subscribe to updates on this page: Vasocon RSS |
| Attenuation of vasoactive oxygen carrier-induced vasoconstriction | 20100051025 | 20100304 |
| Compositions and methods for preventing or reducing vasoconstriction in a mammal following administration of an artificial oxygen carrier (e.g., a hemoglobin-based oxygen carrier) are disclosed. The methods include administering to a mammal a composition containing an artificial oxygen carrier in combination with one or more of a nitric oxide-releasing compound, a therapeutic gas containing gaseous nitric oxide, a phosphodiesterase inhibitor, and/or a soluble guanylate cyclase sensitizer.
... |
| Compositions containing aminoalkanes and aminoalkane derivatives | 20100041622 | 20100218 |
| Provided are palatable liquid compositions that contain 2-aminoalkanes that have vasoconstrictor activity, and other additives, including taste-modifying agents. Also provided are methods for making and using the compositions to provide stimulant activity for increasing energy, alertness, endurance, and/or any other consequent physical manifestation of the vasoconstrictor activity.
... |
| Therapeutic or prophylactic agent for vasoconstriction | 20100035837 | 20100211 |
| The above problems are solved by an agent for treating and preventing vasospasm, cerebral ischemia, or cerebral infarction, comprising trehalose as the active ingredient. It is possible, by using such a trehalose-comprising agent, to suppress phenomena such as contraction of blood vessel and thickening of tunica intima and tunica media and to prevent or treat vasospasm and vasospasm-dependent diseases.
... |
| Vasoconstriction compositions and methods of use | 20100029662 | 20100204 |
| The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
... |
| Compositions and methods for reversing rebound hyperemia | 20100029660 | 20100204 |
| The invention generally relates to compositions and methods for inducing vasoconstriction with low incidence of rebound hyperemia. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
... |
| Preferential vasoconstriction compositions and methods of use | 20100029659 | 20100204 |
| The invention generally relates to compositions and methods for preferential vasoconstriction of smaller blood vessels relative to larger blood vessels. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
... |
| Himf and btk in pulmonary, cardiac and inflammation disorders | 20100028355 | 20100204 |
| Hypoxia induced mitogenic factor (HIMF) is a member of the “found in inflammatory zone” (FIZZ)/resistin family of proteins and has potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. The receptor/binding partners for this family of proteins have been largely unknown. We identified Bruton's tyrosine kinase (BTK) as a functional HIMF binding partner through GST-HIMF pull-downs and mass spectrometry. Using primary cultured HIMF-stimulated murine bone marrow cells, we demonstrated that BTK was recruited to the leading edge of the cells. We also demonstrated that BTK and the closely related tyrosine kinase Fyn, colocalized at the growth cone process in these cells. HIMF stimulation induced BTK autophosphorylation, which peaked at 2.5 minutes. A transwell migration assay showed that treatment with recombinant murine HIMF induced migration of... |
| Compositions and methods for treating acne | 20100021571 | 20100128 |
| This invention provides anti-acne kits that are useful for treating acne, especially severe cases of acne. The anti-acne kits include a vasoconstrictor and an anti-acne agent, and optionally one or more of a a skin lightening therapeutic, a sealing layer, a skin cleanser, an astringent, a skin penetration enhancer, a sunscreen, and nutritional supplements that promote healing of acne lesions. This invention also provides methods for treating acne using a vasoconstrictor in conjunction with an anti-acne agent.
... |
| Systems, methods, and/or apparatuses for non-invasive monitoring of respiratory parameters in sleep disordered breathing | 20100016694 | 20100121 |
| In certain example embodiments, an air delivery system includes a controllable flow generator operable to generate a supply of pressurized breathable gas to be provided to a patient for treatment and a pulse oximeter. In certain example embodiments, the pulse oximeter is configured to determine, for example, a measure of patient effort during a treatment period and provide a patient effort signal for input to control operation of the flow generator. Oximeter plethysmogram data may be used, for example, to determine estimated breath phase; sleep structure information; autonomic improvement in response to therapy; information relating to relative breathing effort, breathing frequency, and/or breathing phase; vasoconstrictive response, etc. Such data may be useful in diagnostic systems.
... |
| Method for treating cardiovascular diseases using rho kinase inhibitor compounds | 20100008968 | 20100114 |
| This invention is directed to methods of preventing or treating diseases or conditions associated with excessive cell proliferation, remodeling, inflammation, and vasoconstriction. Particularly, this invention is directed to methods of treating cardiovascular diseases or conditions such as stent restenosis and thrombosis, vascular thrombosis, cerebral vasospasm, atherosclerosis, systemic hypertension, cardiac hypertrophy, and sexual dysfunction. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel Rho kinase inhibitor compound to treat the disease.
... |
| Control of blood vessel physiology to treat skin disorders | 20100003353 | 20100107 |
| In a method for treating an affected skin region of a patient having a skin disorder, a vasodilation composition is applied to an affected skin region of a patient, the affected skin region exhibiting a skin disorder characterized by at least one abnormal blood vessel, and the affected skin region is then treated so as to non-invasively disrupt tissue architecture, e.g., by inducing ischemia, of the at least one abnormal blood vessel. A vasoconstriction composition can then be applied to the skin region to cause vasoconstriction of the at least one blood vessel in order to promote healing.
... |
| Hypoxia induced mitogenic factor | 20110008349 | 20110113 |
| We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
... |
| Treating patients with subarachnoid hemorrhage | 20110003012 | 20110106 |
| A method for attenuating vasoconstriction in a patient with subarachnoid hemorrhage by administering to the patient a therapeutically effective amount of a compound which mediates an increase of bioactive nitric oxide in blood or tissue in the subarachnoid space to cause vasodilation in cerebral, carotid and basilar arteries after the administration of the compound, and wherein the administration of the compound does not reduce mean arterial blood pressure by more than 10%.
... |
| Monitoring cardiovascular conditions using signal transit times | 20100331708 | 20101230 |
| Methods for monitoring cardiovascular conditions, i.e., hyperdynamic circulation, vasodilation, vasoconstriction, or central-to-peripheral arterial pressure decoupling conditions are described. These methods involve measuring a central signal proportional to or a function of the subject's heart activity and a peripheral signal proportional to or a function of a signal related to the central signal. Then calculating a time difference between features in the central and peripheral signals representing the same heart event. The cardiovascular condition is indicated if the time difference is greater or lower than a threshold value, if the time difference is greater or lower than a threshold value over a specified period of time, or if there is a significant statistical change in the times over the specified time period. These methods can alert a... |
| Compositions and methods for modulation of vascular structure and/or function | 20100323986 | 20101223 |
| The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a β-1-4 conformation.
... |
| Novel bronchodilating alpha, beta-unsaturated isoquinoline amides | 20100256101 | 20101007 |
| The invention relates to novel compounds having the general formula (I), and which compounds are useful to manufacture a medicament to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma, and vasoconstriction, e.g. hypertension.
... |
| New use for cannabinoid-containing plant extracts | 20100249223 | 20100930 |
| The present invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of diseases or conditions that are alleviated by blockade of one or more types of TRP channel. Preferably the subset of TRP channel that is blockaded is the TRPA channel. More preferably the TRPA channel is the TRPA1 channel. Preferably the diseases or conditions to be prevented or treated include: neuropathic pain, inflammation or vasoconstriction. Alternatively the TRP channel that is blockaded is the TRPM channel. More preferably the TRPM channel is the TRPM8 channel. Preferably the diseases or conditions to be prevented or treated are cancer. More preferably the cancers to be treated include: cancer of the prostate, cancer of the breast, cancer of the colon, cancer of the... |
| Methods for the diagnosis and for the treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists | 20100209433 | 20100819 |
| Submitted herewith is a sequence listing in computer readable form for entry into the present application. Also enclosed is a pdf copy of the as-filed sequence listing and a Checker Program report indicating that the text file of the sequence listing contains no errors.
... |
| Indications for local transport of anaesthetic agents by electrotransport devices | 20100191216 | 20100729 |
| The use of an iontophoresis electrode assembly for delivery of a drug formulation is described. The drug formulation includes an anaesthetic and a vasoconstrictor. It is administered to a patient prior to a procedure to produce clinically acceptable depth and duration of dermal anaesthesia at the portion of skin to subject to a painful procedure or to reduce or eliminate pain. The procedure is one selected from the group consisting of venipuncture, IV cannulation, needle aspirations, body piercings, blood donations, electrolysis, tattoo removal, tattoo application, injections, dermabrasion, skin peeling, high velocity particle ablation, pace maker implantation, pace maker replacement, epidural puncture, lumbar puncture, regional nerve blocks, skin harvesting, small skin incisions, skin biopsies, circumcisions or excisions. The iontophoresis electrode assembly may also be used to reduce... |
| Methods of nasopharyngeal cooling for augmenting coronary perfusion pressure | 20100174278 | 20100708 |
| A method for improving the success of resuscitation efforts following cardiac arrest is provided. Return of spontaneous circulation (ROSC) rates following cardiac arrest is directly related to the coronary perfusion pressure during cardiopulmonary resuscitation (CPR). Selective cooling of the nasal cavity, nasopharynx, oral cavity, oropharynx, retrotonsillar space, mouth, neck face, and/or throat of a patient suffering from cardiac arrest, significantly increases the coronary perfusion pressure which improves ROSC rates. Cooling may be initiated before or during resuscitation efforts including chest compressions, defibrillation and/or administering a vasoconstrictor.
... |
| Composition for treatment of common cold | 20100093783 | 20100415 |
| New stable compositions comprising the combination of a topically active vasoconstrictor and a topically active anticholinergic drug are disclosed. Preferably, the composition comprises ipratropium or a salt thereof in combination with xylometazoline hydrochloride and a salt thereof. Upon topically administering such compositions to a nasal mucosa in individuals suffering from the common cold the symptoms of rhinorrhea are significantly reduced.
... |
| Polyanhydrides with therapeutically useful degradation products | 20100074937 | 20100325 |
| is disclosed, wherein Ar and R are selected so that the aromatic polyanhydride hydrolyzes to form a therapeutic salicylate, another non-steroidal anti-inflammatory, an antifibrotic aminobenzoate, or a vasoconstricting phenylethanolamine. Implantable medical devices, such as scaffolding implants for tissue reconstruction, drug delivery systems prepared from the aromatic polyanhydrides, as well as therapeutic dosage forms and treatment methods are also disclosed.
... |
| Endothelin receptor antagonists | 20100063076 | 20100311 |
| This invention relates to novel endothelin receptor antagonists, derivatives, acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by compounds that block the endothelin signaling pathway that leads to vasoconstriction and in particular those diseases or conditions beneficially treated by endothelin receptor antagonists.
... |
| Composition and method for treating hemorrhoids and/or anorectal disorders | 20100055185 | 20100304 |
| The invention provides an oil-in-water emulsion useful in the treatment of anorectal disorders comprising a local anesthetic, vasoconstrictor, glycerin and water, and method of preparation of the emulsion and a method for treating hemorrhoids using the composition of the invention.
... |
| Attenuation of vasoactive oxygen carrier-induced vasoconstriction | 20100051025 | 20100304 |
| Compositions and methods for preventing or reducing vasoconstriction in a mammal following administration of an artificial oxygen carrier (e.g., a hemoglobin-based oxygen carrier) are disclosed. The methods include administering to a mammal a composition containing an artificial oxygen carrier in combination with one or more of a nitric oxide-releasing compound, a therapeutic gas containing gaseous nitric oxide, a phosphodiesterase inhibitor, and/or a soluble guanylate cyclase sensitizer.
... |
| Compositions containing aminoalkanes and aminoalkane derivatives | 20100041622 | 20100218 |
| Provided are palatable liquid compositions that contain 2-aminoalkanes that have vasoconstrictor activity, and other additives, including taste-modifying agents. Also provided are methods for making and using the compositions to provide stimulant activity for increasing energy, alertness, endurance, and/or any other consequent physical manifestation of the vasoconstrictor activity.
... |
| Therapeutic or prophylactic agent for vasoconstriction | 20100035837 | 20100211 |
| The above problems are solved by an agent for treating and preventing vasospasm, cerebral ischemia, or cerebral infarction, comprising trehalose as the active ingredient. It is possible, by using such a trehalose-comprising agent, to suppress phenomena such as contraction of blood vessel and thickening of tunica intima and tunica media and to prevent or treat vasospasm and vasospasm-dependent diseases.
... |
| Vasoconstriction compositions and methods of use | 20100029662 | 20100204 |
| The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
... |
| Compositions and methods for reversing rebound hyperemia | 20100029660 | 20100204 |
| The invention generally relates to compositions and methods for inducing vasoconstriction with low incidence of rebound hyperemia. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
... |
| Preferential vasoconstriction compositions and methods of use | 20100029659 | 20100204 |
| The invention generally relates to compositions and methods for preferential vasoconstriction of smaller blood vessels relative to larger blood vessels. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
... |
| Himf and btk in pulmonary, cardiac and inflammation disorders | 20100028355 | 20100204 |
| Hypoxia induced mitogenic factor (HIMF) is a member of the “found in inflammatory zone” (FIZZ)/resistin family of proteins and has potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. The receptor/binding partners for this family of proteins have been largely unknown. We identified Bruton's tyrosine kinase (BTK) as a functional HIMF binding partner through GST-HIMF pull-downs and mass spectrometry. Using primary cultured HIMF-stimulated murine bone marrow cells, we demonstrated that BTK was recruited to the leading edge of the cells. We also demonstrated that BTK and the closely related tyrosine kinase Fyn, colocalized at the growth cone process in these cells. HIMF stimulation induced BTK autophosphorylation, which peaked at 2.5 minutes. A transwell migration assay showed that treatment with recombinant murine HIMF induced migration of... |
| Compositions and methods for treating acne | 20100021571 | 20100128 |
| This invention provides anti-acne kits that are useful for treating acne, especially severe cases of acne. The anti-acne kits include a vasoconstrictor and an anti-acne agent, and optionally one or more of a a skin lightening therapeutic, a sealing layer, a skin cleanser, an astringent, a skin penetration enhancer, a sunscreen, and nutritional supplements that promote healing of acne lesions. This invention also provides methods for treating acne using a vasoconstrictor in conjunction with an anti-acne agent.
... |
| Systems, methods, and/or apparatuses for non-invasive monitoring of respiratory parameters in sleep disordered breathing | 20100016694 | 20100121 |
| In certain example embodiments, an air delivery system includes a controllable flow generator operable to generate a supply of pressurized breathable gas to be provided to a patient for treatment and a pulse oximeter. In certain example embodiments, the pulse oximeter is configured to determine, for example, a measure of patient effort during a treatment period and provide a patient effort signal for input to control operation of the flow generator. Oximeter plethysmogram data may be used, for example, to determine estimated breath phase; sleep structure information; autonomic improvement in response to therapy; information relating to relative breathing effort, breathing frequency, and/or breathing phase; vasoconstrictive response, etc. Such data may be useful in diagnostic systems.
... |
| Method for treating cardiovascular diseases using rho kinase inhibitor compounds | 20100008968 | 20100114 |
| This invention is directed to methods of preventing or treating diseases or conditions associated with excessive cell proliferation, remodeling, inflammation, and vasoconstriction. Particularly, this invention is directed to methods of treating cardiovascular diseases or conditions such as stent restenosis and thrombosis, vascular thrombosis, cerebral vasospasm, atherosclerosis, systemic hypertension, cardiac hypertrophy, and sexual dysfunction. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel Rho kinase inhibitor compound to treat the disease.
... |
| Control of blood vessel physiology to treat skin disorders | 20100003353 | 20100107 |
| In a method for treating an affected skin region of a patient having a skin disorder, a vasodilation composition is applied to an affected skin region of a patient, the affected skin region exhibiting a skin disorder characterized by at least one abnormal blood vessel, and the affected skin region is then treated so as to non-invasively disrupt tissue architecture, e.g., by inducing ischemia, of the at least one abnormal blood vessel. A vasoconstriction composition can then be applied to the skin region to cause vasoconstriction of the at least one blood vessel in order to promote healing.
... |
| Method for treating pulmonary diseases using rho kinase inhibitor compounds | 20090325958 | 20091231 |
| This invention is directed to methods of preventing or treating diseases or conditions of the lungs associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema. Particularly, this invention is directed to methods of treating pulmonary diseases such as asthma; chronic obstructive pulmonary disease; respiratory tract illness caused by respiratory syncytial virus; pulmonary arterial hypertension; acute respiratory distress syndrome and ventilator induced lung injury; cystic fibrosis; bronchiectasis; alpha-1-antitrypsin deficiency; rhinitis; rhinosinusitis; primary ciliary dyskinesia; pneumonia; bronchiolitis caused by agents other than respiratory syncytial virus; and interstitial lung disease including lymphangioleiomyomatosis; idiopathic pulmonary fibrosis; obliterative bronchiolitis or bronchiolitis obliterans organizing pneumonia due to lung transplantation or HSCT; nonspecific interstitial pneumonia; cryptogenic organizing pneumonia; acute interstitial pneumonia; respiratory bronchiolitis-associated interstitial lung disease; or pulmonary sarcoidosis.... |
| Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor | 20090318459 | 20091224 |
| or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved.
... |
| Ophthalmic percutaneous absorption type preparation | 20090318422 | 20091224 |
| The present invention provides an ophthalmic percutaneous absorption type preparation containing an ophthalmic drug and a vasoconstrictor, which can increase the amount of the ophthalmic drug transferred through the eyelid to a topical area in the eye, particularly the anterior segment of the eye such as conjunctiva, lacrimal fluid, aqueous humor, cornea and the like by administration to the skin surface of an eyelid.
... |
| Compositions and methods for modulation of vascular structure and/or function | 20090318383 | 20091224 |
| The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a β-1-4 conformation.
... |
| Iontophoresis drug delivery formulation providing acceptable sensation and dermal anesthesia | 20090312688 | 20091217 |
| A shelf-stable electrically assisted transdermal drug delivery system for highly effective electrotransport of an anesthetic and a vasoconstrictor producing clinically acceptable dermal anesthesia and sensation is provided. In certain embodiments the anesthetic includes lidocaine and the vasoconstrictor includes epinephrine. Medicament delivery is affected to provide dermal anesthesia with little or no sensation during delivery, as measured by a variety of indicator tests. Methods of producing dermal anesthesia in patients are also provided.
... |
| Non-flushing niacin analogues, and methods of use thereof | 20090312355 | 20091217 |
| One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.
... |
| Modulation of the p2y2 receptor pathway | 20090306009 | 20091210 |
| The present invention relates to the field of regulating the activity of the purinergic receptors for the modulation of the vascular tone, particularly for the purpose of treatment of haemodynamic conditions by overriding of vasoconstriction activity, such as increases in sympathic vasoconstriction. Modulators, such as UTP analogues as described herein are preferably specific for P2Y2. Compounds capable of stimulating the P2Y2 receptor are suitable for the treatment or prevention wherein inhibition of vasoconstriction activity is desirable such as hypertension and hypertension relates disorders or diseases, whereas compound capable of counteracting the activity of the P2Y2 receptor are suitable for the treatment of or prevention wherein inhibition of vasodilatation is desirable.
... |
| Methods of increasing cerebral blood flow | 20090270328 | 20091029 |
| Methods of increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or vasospasm following hemorrhagic stroke; due to chronic high blood pressure; and/or due to idiopathic causes are provided. The method for increasing blood flow in such a mammalian brain blood vessel includes administering to a patient in need thereof a therapeutically effective amount of an inhibitor of δ protein kinase C. In certain embodiments, the inhibitor can be chronically administered without causing desensitization of the patient to the inhibitor. Kits for increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or... |
| Methods of increasing cerebral blood flow | 20090270328 | 20091029 |
| Methods of increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or vasospasm following hemorrhagic stroke; due to chronic high blood pressure; and/or due to idiopathic causes are provided. The method for increasing blood flow in such a mammalian brain blood vessel includes administering to a patient in need thereof a therapeutically effective amount of an inhibitor of δ protein kinase C. In certain embodiments, the inhibitor can be chronically administered without causing desensitization of the patient to the inhibitor. Kits for increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or... |
| No-modified hemoglobins and uses therefor | 20090253615 | 20091008 |
| Nitrosylhemoglobin can be produced by introducing gaseous NO into an aqueous solution of hemoglobin. It has been demonstrated that nitrosylhemoglobin in aqueous solution can be converted to SNO-hemoglobin upon introduction of oxygen to the solution, as is postulated to occur in the lungs. Nitrosylhemoglobin can be used in methods to produce the physiological effects of NO, for example, to reduce vasoconstriction and to inhibit platelet aggregation.
... |
| Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibiton of pain and inflammation | 20090253795 | 20091008 |
| A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.
... |
| No-modified hemoglobins and uses therefor | 20090253615 | 20091008 |
| Nitrosylhemoglobin can be produced by introducing gaseous NO into an aqueous solution of hemoglobin. It has been demonstrated that nitrosylhemoglobin in aqueous solution can be converted to SNO-hemoglobin upon introduction of oxygen to the solution, as is postulated to occur in the lungs. Nitrosylhemoglobin can be used in methods to produce the physiological effects of NO, for example, to reduce vasoconstriction and to inhibit platelet aggregation.
... |
| Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibiton of pain and inflammation | 20090253795 | 20091008 |
| A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.
... |
| Viagra | 20090246298 | 20091001 |
| 3. Skull Cap works on the body using the volatile fixed oils, (essential oil) The main color titrated out is green, green works on the heart. In the Contraction phase the heart rests. There are seven botanical herbs in the Magistral Viagra. The synergistic effect causes the free flow of hormones in Endocrine system, (duct-less glands) to operate efficiently. It helps to rid the body of diseased bacteria and gives the patient confidence in coitus.
... |
| Sclerotherapy for varicose veins | 20090202467 | 20090813 |
| This invention is directed to pharmaceutical compositions and methods of treating varicose veins, including telangiectasias and reticular veins, and related symptoms and diseases. Embodiments comprise injection into a varicose vein of an amphiphilic block copolymer which has properties of conversion from liquid to gel state, surfactant properties, or combinations thereof. Other embodiments consist of the combination of an amphiphilic block copolymer with a co-solvent, also allowing the injected combination to form a gel within the vein. In other embodiments, an amphiphilic block copolymer is combined with a co-solvent, a sclerosant, a vasoconstrictor, water, or combinations thereof. Other embodiments of the invention include a combination of a sclerosant such as sodium tetradecyl sulfate or polidocanol with a vasoconstrictor, preferably a long-acting vasoconstrictor such as oxymetazoline. Other embodiments... |
| Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists | 20090191220 | 20090730 |
| The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used as for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM but insufficient levels of pro-END immunoreactivities with a medicament comprising vasoconstrictive endothelin or its precursors, and/or endothelin agonists or adrenomedullin antagonists is provided.
... |
| Compositions for the treatment and prevention of eyelid swelling | 20090136598 | 20090528 |
| The invention features topical formulations comprising an osmotically active agent and/or a vasoconstrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.
... |
| Methods of treating pulmonary disease using acetazolamide and structurally related derivatives | 20090131490 | 20090521 |
| wherein R1, R2 or R3 are each independently a C1 to C6 alkyl, a halogen, a sulfate, or a phosphate. The pulmonary disease in the subject can be hypoxic pulmonary vasoconstriction, pulmonary edema, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial fibrosis, high altitude residence, sleep apnea syndrome, atrial septal defects, and pulmonary diseases associated with other conditions. If this same compound is modified so that R1, R2 or R3 each independently is a C1 to C6 alkyl and the compound is not a carbonic acid inhibitor, it can be administered to a subject to block hypoxic pulmonary vasoconstriction and/or prevent high altitude pulmonary edema. Additional aspects of the present invention include an inhalable composition comprising the compound of the above formula without modification... |
| Injectable capsaicin with vasocontrictor adjunctive agent | 20090117167 | 20090507 |
| Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and coadministering a vasoconstrictor.
... |
| Compositions and methods for promoting hemostasis and other physiological activities | 20090111734 | 20090430 |
| Compositions that include nanoscale structured materials or precursors thereof (e.g., self-assembling peptides) are described. The compositions can include other substances (e.g., a vasoconstrictor). Also described are methods for using the compositions to promote hemostasis, to protect the skin or wounds from contamination, to decontaiminate a site upon removal of previously applied compositions that provided a protective coating, and to inhibit the movement of bodily substances other than blood. The compositions are also useful in isolating tissue, removing tissue, preserving tissue (for, e.g., subsequent transplantation or reattachment), and as bulking, stabilizing or hydrating agents. Medical devices that include the compositions (e.g., a stent or catheter), bandages or other wound dressings, sutures, and kits that include the compositions are also described.
... |
| Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate | 20090068264 | 20090312 |
| Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL). The invention is useful for the amelioration of diabetes mellitus types 1 and 2 (including impaired glucose tolerance, pre-diabetes, insulin resistance, metabolic syndrome X and as an adjunct to oral antidiabetic agents and/or insulin), diabetic and non-diabetic microvascular diseases (including nephropathy, neuropathy and retinopathy), diabetic and non-diabetic macrovascular diseases (including heart attack, stroke, peripheral vascular disease and ischemia-reperfusion injury), hypertension, vasoconstriction, obesity, dyslipedemia, and neurodegenerative disorders (including Parkinson's disease, mild cognitive impairment, senile dementia, Alzheimer's disease,... |
| Compositions comprising antihistamines or mast cell stabilizers, and methods of making and using same | 20090005362 | 20090101 |
| Compositions comprise: (a) a material selected from the group consisting of antihistamines, stabilizers, salts thereof, and combinations thereof; and (b) a vasoconstrictor, decongestant, or a salt thereof, provided when the material consists of an antihistamine or a salt thereof, at least one antihistamine other than ketotifen and salts thereof is present. In certain embodiments, the compositions have a pH maintainable at about 5 or less during storage. The compositions can be used to treat, alleviate or ameliorate ocular allergic conditions.
... |
| Endothelin receptor antagonists | 20090005394 | 20090101 |
| This invention relates to novel endothelin receptor antagonists, derivatives, acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by compounds that block the endothelin signaling pathway that leads to vasoconstriction and in particular those diseases or conditions beneficially treated by endothelin receptor antagonists.
... |
| Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system | 20080305077 | 20081211 |
| Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to, inter alia, the CNS applied via intranasal administration while reducing non-target exposure are provided. In certain embodiments, at least one vasoconstrictor is provided intranasally prior to intranasal administration of at least one therapeutic compound. In other embodiments, the vasoconstrictor(s) and therapeutic compound(s) are combined in a pharmaceutical composition and delivered intranasally. The present invention substantially increases targeting of the therapeutic compound(s) to, inter alia, the CNS while substantially reducing unwanted and potentially harmful systemic exposure. The preferred administration of the invention applies the vasoconstrictor(s) and/or therapeutic compound(s) to the upper third of the nasal cavity, though application to the lower two-thirds of the nasal cavity is also within the scope of the invention.
... |
| Topical preparation and method for transdermal delivery and localization of therapeutic agents | 20080293703 | 20081127 |
| Disclosed herein is a preparation for topically delivering and localizing therapeutic agents, comprising: a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; and a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Further disclosed is an associated method of topically delivering and localizing therapeutic agents, comprising the steps of: using a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; in combination with using a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Also disclosed are various courses of treatment, which comprise applying the various disclosed combinations of agents to the patient's skin.
... |
| Method of using vasoconstrictive agents during energy-based tissue therapy | 20080275068 | 20081106 |
| A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation. This treatment method increases or promotes the size of the coagulation zone created after energy-based therapy.
... |
| Method and apparatus for applying energy to biological tissue including the use of tumescent tissue compression | 20080249519 | 20081009 |
| An electrode catheter is introduced into a hollow anatomical structure, such as a vein, and is positioned at a treatment site within the structure. Tumescent fluid is injected into the tissue surrounding the treatment site to produce tumescence of the surrounding tissue which then compresses the vein. The solution may include an anesthetic, and may further include a vasoconstrictive drug that shrinks blood vessels. The tumescent swelling in the surrounding tissue causes the hollow anatomical structure to become compressed, thereby exsanguinating the treatment site. Energy is applied by an electrode catheter in apposition with the vein wall to create a heating effect. The heating effect causes the hollow anatomical structure to become molded and durably assume the compressed dimensions caused by the tumescent technique. The electrode... |
| Drug delivery and method having coated microprojections incorporating vasoconstrictors | 20080226687 | 20080918 |
| A device and method are provided for percutaneous transdermal delivery of a biologically active agent. The coating formulation containing the biologically active agent and a vasoconstrictor is applied to the skin piercing elements using known coating techniques and then dried. The device is applied to the skin of a living animal, causing the microprojections to pierce the stratum corneum and to deliver an effective dose of the biologically active agent and vasoconstrictor to the animal.
... |
| Devices and methods for selectively lysing cells | 20080200863 | 20080821 |
| A system comprising: a container containing a measured amount of a solution including at least one of a vasoconstrictor, a surfactant, and an anesthetic, the solution comprising a liquid and at least one of a gas and a fluid; a needle array in fluid connection with the container, the needle array including at least one needle.
... |
| Patient temperature regulation method and apparatus | 20080200970 | 20080821 |
| A device and method for providing body cooling. The cooling device applies cooling to blood flowing in a vena cavae that is then distributed throughout the body. The cooling can be assisted by use of thermoregulatory drugs or warming devices to prevent shivering and vasoconstriction.
... |
| Use of high dose concentrations of gaseous nitric oxide | 20080193566 | 20080814 |
| The invention relates to a methods and devices of delivering gaseous nitric oxide to a mammal or surface at a concentration ranging from about 1000 ppm to about 50,000 ppm of gaseous nitric oxide. Different conditions which can be treated by high dosage administration of gNO include but are not limited to: topical treatments with gNO, cosmetic applications of gNO, vasodilation conditions with gNO, inhalation treatments with gNO, treatments of the blood with gNO, treatment of the skin or tissue with gNO, treatment of infections with gNO, treatment of inflammation on or within the body, and treatments of biofilms with gNO. Other conditions, aliments, or symptoms that may be treated with high dosage gNO include bronchoconstriction, reversible pulmonary vasoconstriction, asthma, pulmonary hypertension, adult respiratory distress syndrome... |
| Methods and devices for the non-thermal, electrically-induced closure of blood vessels | 20080188846 | 20080807 |
| Methods and devices for the non-thermal, electrically-induced temporary or permanent closure of blood vessels. The subject methods and devices employ pulsed electrical energy according to a defined regime to effect controlled occlusion of targeted blood vessels without heating the vessel and with minimal damage to adjacent tissue. The extent of vessel closure, i.e., temporary (vasoconstriction) or permanent (thrombosis), is controlled based on the manipulation of various parameters of the electrical stimulation regime as well as the configuration of the electrodes used to apply the regime.
... |
| Method for treating bronchoconstriction and pulmonary vaso-constriction | 20080138444 | 20080612 |
| This invention relates to the treatment and prevention of asthma or other forms of broncho-constriction or reversible pulmonary vasoconstriction in a mammal.
... |
| Method and device for cardiac vasoactive therapy | 20080132972 | 20080605 |
| A method and device for treating myocardial ischemia in which an implantable pulse generator delivers electrical stimulation to electrodes disposed near a coronary artery. The stimulation parameters may be adjusted to produce vasodilation and/or vasoconstriction of the artery. The device may be configured to operate in a vasodilation and/or vasoconstriction mode in accordance with specified entry and exit conditions.
... |
| Modulators of pulmonary hypertension | 20080095711 | 20080424 |
| Compounds, compositions, and methods for inhibiting pulmonary hypertension are disclosed. The invention is particularly directed to the use of agents that specifically inhibit the activity of certain endogenously produced epoxyeicosatrienoic acids that promote vasoconstriction of pulmonary arteries. These agents are particularly useful for inhibiting hypoxia-induced pulmonary hypertension. The invention further discloses additional compounds, compositions and methods for increasing pulmonary hypertension.
... |
| Topical anesthetic composition | 20080085245 | 20080410 |
| A method for providing anesthesia to a subject having a wound, such as a laceration, a surgical incision, an ulcer, an abrasion or a burn, said method comprising the step of applying topically to the wound a composition comprising: at least one local anesthetic agent; a hydrophilic or hydroalcoholic gelling agent; an antiseptic agent; a vasoconstrictor; and a detectable marker such as a food dye, wherein when the composition is topically applied to the wound of the subject the presence of the anesthetic agent on the subject is indicated by the detectable marker. The method has been developed primarily for anaesthetizing open wounds of animals, particularly those caused by husbandry procedures.
... |
| Method and apparatus for applying energy to biological tissue including the use of tumescent tissue compression | 20080039793 | 20080214 |
| An electrode catheter is introduced into a hollow anatomical structure, such as a vein, and is positioned at a treatment site within the structure. Tumescent fluid is injected into the tissue surrounding the treatment site to produce tumescence of the surrounding tissue which then compresses the vein. The solution may include an anesthetic, and may further include a vasoconstrictive drug that shrinks blood vessels. The tumescent swelling in the surrounding tissue causes the hollow anatomical structure to become compressed, thereby exsanguinating the treatment site. Energy is applied by an electrode catheter in apposition with the vein wall to create a heating effect. The heating effect causes the hollow anatomical structure to become molded and durably assume the compressed dimensions caused by the tumescent technique. The electrode... |
| Method and apparatus for applying energy to biological tissue including the use of tumescent tissue compression | 20080039829 | 20080214 |
| An electrode catheter is introduced into a hollow anatomical structure, such as a vein, and is positioned at a treatment site within the structure. Tumescent fluid is injected into the tissue surrounding the treatment site to produce tumescence of the surrounding tissue which then compresses the vein. The solution may include an anesthetic, and may further include a vasoconstrictive drug that shrinks blood vessels. The tumescent swelling in the surrounding tissue causes the hollow anatomical structure to become compressed, thereby exsanguinating the treatment site. Energy is applied by an electrode catheter in apposition with the vein wall to create a heating effect. The heating effect causes the hollow anatomical structure to become molded and durably assume the compressed dimensions caused by the tumescent technique. The electrode... |
| Hemostatic compound and its use | 20080014251 | 20080117 |
| A novel hemostatic compound includes a hemostatic agent and a transdermal migration-enhancing agent, the agents combined in a defined ratio and in a form capable of topical application to an abrasion, puncture or incision site and capable at the site of inhibiting bleeding. In accordance with one embodiment of the invention, the hemostatic agent is a vasoconstrictor and/or a procoagulant, and the agents are combined in a liquid or semi-liquid form. A compound-gelling agent and/or an evaporative agent and/or an evaporative gel can be combined with the hemostatic and migration-enhancing agents in a defined ratio. In accordance with another embodiment of the invention, the invented hemostatic compound includes a hemostatic agent and a compound-gelling agent, the latter being more particularly an evaporative gel. Other components such... |
| Hemostatic compound and its use | 20080015480 | 20080117 |
| A novel hemostatic compound includes a hemostatic agent and a transdermal migration-enhancing agent, the agents combined in a defined ratio and in a form capable of topical application to an abrasion, puncture or incision site and capable at the site of inhibiting bleeding. In accordance with one embodiment of the invention, the hemostatic agent is a vasoconstrictor and/or a procoagulant, and the agents are combined in a liquid or semi-liquid form. A compound-gelling agent and/or an evaporative agent and/or an evaporative gel can be combined with the hemostatic and migration-enhancing agents in a defined ratio. In accordance with another embodiment of the invention, the invented hemostatic compound includes a hemostatic agent and a compound-gelling agent, the latter being more particularly an evaporative gel. Other components such... |
| No-modified hemoglobins and uses therefor | 20070275878 | 20071129 |
| Nitrosylhemoglobin can be produced by introducing gaseous NO into an aqueous solution of hemoglobin. It has been demonstrated that nitrosylhemoglobin in aqueous solution can be converted to SNO-hemoglobin upon introduction of oxygen to the solution, as is postulated to occur in the lungs. Nitrosylhemoglobin can be used in methods to produce the physiological effects of NO, for example, to reduce vasoconstriction and to inhibit platelet aggregation.
... |
| Compositions for the treatment and prevention of eyelid swelling | 20070264318 | 20071115 |
| The invention features topical formulations comprising an osmotically active agent and/or a vasoconstrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.
... |
| Toxin induced sympathectomy | 20070264373 | 20071115 |
| A selective and extended sympathetic nerve block is achieved by administration of a botulinum toxin at and/or around a targeted sympathetic ganglion. The toxin induced sympathetic block finds use for the treatment of sympathetically maintained pain. The toxin induced sympathetic block is also used to treat cardiovascular conditions of sympathetically maintained vasoconstriction; and of undesirable smooth muscle spasm.
... |
| Therapeutic avenanthramide compounds | 20070254055 | 20071101 |
| Methods and compositions are disclosed for inhibiting proliferation of human colon adenocarcinoma cells, reducing pro-inflammatory molecules, adhesion molecules, and vascular smooth muscle cell proliferation, and for increasing NO production. The present invention describes the use of phenolic compositions, purified from oats or synthetically produced, to decrease the effective amount of pro-inflammatory molecules and/or cell adhesion molecules. Alternatively, an alcoholic extract or concentrate from oats can be used. The methods of the present invention can be used as a treatment or prophylaxis of a wide variety of disorders associated with inflammatory states and/or with a lack of or need for nitric oxide (NO), such as inflammatory conditions, pain, free radical associated disorders, cardiovascular diseases, autoimmune disorders, pathological platelet aggregation, pathological vasoconstriction, vascular effects of diabetes, stroke, atherosclerosis,... |
| Methods and devices to induce controlled atelectasis and hypoxic pulmonary vasoconstriction | 20070225747 | 20070927 |
| Lung conditions are treated by implanting a flow restrictor in a passageway upstream from a diseased lung segment. The restrictor will create an orifice at the implantation site which inhibits air exchange with the segment to induce controlled atelectasis and/or hypoxia. Controlled atelectasis can induce collapse of the diseased segment with a reduced risk of pneumothorax. Hypoxia can promote gas exchange with non-isolated, healthy regions of the lung even in the absence of lung collapse.
... |
| Polyanhydrides with therapeutically useful degradation products | 20070213500 | 20070913 |
| is disclosed, wherein Ar and R are selected so that the aromatic polyanhydride hydrolyzes to form a therapeutic salicylate, another non-steroidal anti-inflammatory, an antifibrotic aminobenzoate, or a vasoconstricting phenylethanolamine. Implantable medical devices, such as scaffolding implants for tissue reconstruction, drug delivery systems prepared from the aromatic polyanhydrides, as well as therapeutic dosage forms and treatment methods are also disclosed.
... |
| Infiltration cannula | 20070213688 | 20070913 |
| An infiltration cannula and method of using the infiltration cannula during a tumescent infiltration procedure are disclosed herein. The infiltration cannula may have an outwardly flaring hub which may be wedged into an adit of a patient to minimize leakage of fluid being infiltrated into the patient. Also, the infiltration cannula may be utilized to hydrate a dehydrated patient by a medically untrained person. The infiltration cannula may also be used to deliver an antibiotic/vasoconstrictive drug solution to minimize surgical site infections.
... |
| Method of using vasoconstrictive agents during energy-based tissue therapy | 20070208042 | 20070906 |
| A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation. This treatment method increases or promotes the size of the coagulation zone created after energy-based therapy.
... |
| Compositions for enhancing sexual responsiveness | 20070202199 | 20070830 |
| A topical composition which enhances sexual responsiveness of a mammal is disclosed. An effective dosage of a peripheral vasodilator, an absorption enhancer and, optionally, a vasoconstrictor and an alpha receptor blocker are combined with a pharmaceutically-acceptable topical vehicle to produce the composition. The compositions are applied topically to the penis or labia majora and minora pudenda to enhance erection or vasocongestion.
... |
| Compositions and methods for promoting hemostasis and other physiological activities | 20070203062 | 20070830 |
| Compositions that include nanoscale structured materials or precursors thereof (e.g., self-assembling peptides) are described. The compositions can include other substances (e.g., a vasoconstrictor). Also described are methods for using the compositions to promote hemostasis, to protect the skin or wounds from contamination, to decontaminate a site upon removal of previously applied compositions that provided a protective coating, and to inhibit the movement of bodily substances other than blood. The compositions are also useful in isolating tissue, removing tissue, preserving tissue (for, e.g., subsequent transplantation or reattachment), and as bulking, stabilizing or hydrating agents. Medical devices that include the compositions (e.g., a stent or catheter), bandages or other wound dressings, sutures, and kits that include the compositions are also described.
... |
| Methods of distinguishing between vasoconstriction and vasodiltation as a cause of hypotension | 20070179384 | 20070802 |
| The present invention relates to the use of the arterial pressure waveform recorded invasively or non-invasively, to distinguish between compensatory vasoconstriction with low cardiac output on the one hand from vasodilation from more severe organ damage on the other, as a cause of hypotension in acute emergencies. The waveforms may be subjected to harmonic analysis and the moduli of their harmonic components compared whereby a hypotensive individual can be confirmed to have the higher the first harmonic is considered as having vasoconstriction as a cause of hypotension.
... |
| Method and composition for treating otitis media | 20070173463 | 20070726 |
| A combination of agents for use at the time of placement of tubes in the eardrums is presented specifically to address both the issue of infection and the issue of tube obstruction from blood. Tube placement for chronic fluid behind the eardrum or recurrent ear infections is one of the most commonly performed procedures. It is not uncommon for a small amount of blood to accumulate and block a tube placed in the eardrum. The eardrop formulation disclosed herein contains any of various antibiotics which have heretofore been placed at the time of tube placement plus a vasoconctrictor not only to treat infection and reduce the likelihood of chronic drainage from the tube and therefore ear drainage but also to prevent or minimize bleeding at or... |
| Iontophoresis drug delivery device providing acceptable depth and duration of dermal anesthesia | 20070093743 | 20070426 |
| An electrically assisted transdermal drug delivery system for highly effective electrotransport of an anesthetic and a vasoconstrictor producing clinically acceptable depth and duration of dermal anesthesia at a treatment site. In certain embodiments, the anesthetic comprises lidocaine and the vasoconstrictor comprises epinephrine.
... |
| Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy | 20070077219 | 20070405 |
| Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.
... |
| Iontophoresis drug delivery formulation providing acceptable sensation and dermal anesthesia | 20070078372 | 20070405 |
| A shelf-stable electrically assisted transdermal drug delivery system for highly effective electrotransport of an anesthetic and a vasoconstrictor producing clinically acceptable dermal anesthesia and sensation is provided. In certain embodiments the anesthetic includes lidocaine and the vasoconstrictor includes epinephrine. Medicament delivery is affected to provide dermal anesthesia with little or no sensation during delivery, as measured by a variety of indicator tests. Methods of producing dermal anesthesia in patients are also provided.
... |
| Indications for local transport of anaesthetic agents by electrotransport devices | 20070078434 | 20070405 |
| The use of an iontophoresis electrode assembly for delivery of a drug formulation is described. The drug formulation includes an anaesthetic and a vasoconstrictor. It is administered to a patient prior to a procedure to produce clinically acceptable depth and duration of dermal anaesthesia at the portion of skin to subject to a painful procedure or to reduce or eliminate pain. The procedure is one selected from the group consisting of venipuncture, IV cannulation, needle aspirations, body piercings, blood donations, electrolysis, tattoo removal, tattoo application, injections, dermabrasion, skin peeling, high velocity particle ablation, pace maker implantation, pace maker replacement, epidural puncture, lumbar puncture, regional nerve blocks, skin harvesting, small skin incisions, skin biopsies, circumcisions or excisions. The iontophoresis electrode assembly may also be used to reduce... |
| Compositions and methods for modulation of vascular structure and/or function | 20070072826 | 20070329 |
| The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a β-1-4 conformation.
... |
| Wound dressing and adhesive wound dressing comprising a vasoconstrictive ingredient, and processes for the production thereof | 20070073210 | 20070329 |
| A wound dressing provided as a ready-made product for covering bleeding wounds. The wound dressing comprises a carrier material containing at least one vasoconstrictive medicinal substance.
... |
| Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods | 20070059351 | 20070315 |
| The present invention is drawn to a transdermal patch for the delivery of a nitric oxide-donor and a second active agent. The patch can comprise a backing layer and an active agent-containing composition which is supported at least in part by the backing layer. The active agent-containing composition can include an amount of a nitric oxide-donor and an amount of a second active agent. The transdermal patch can have a drug delivery zone defined by the area where the composition contacts an intact human skin site, and the transdermal patch can be formulated to deliver a nitric oxide donor, such as nitroglycerin, at from about 5 μg/hour to about 85 μg/hour. The second active agent can be selected from a number of agents including NSAIDS, opioids,... |
| Controlled heat transfer with mammalian bodies | 20070060987 | 20070315 |
| Methods, computer programming and devices for transferring heat to and/or from a body portion of a mammal are provided. One approach includes directly determining a state of vasoconstriction or vasodilation in a portion of a body, and supplying heat to the portion of the body when vasoconstriction is determined, and removing heat from the portion of the body when vasodilation is determined. The body portion preferably includes specific heat exchange vasculature. In another approach, a transition of the body portion from a state of vasodilation to vasoconstriction is determined and the body portion is then actively kept in a state of vasodilation while removing heat therefrom.
... |
| Compositions and methods for treating acne | 20070048234 | 20070301 |
| This invention provides anti-acne kits that are useful for treating acne, especially severe cases of acne. The anti-acne kits include a vasoconstrictor and an anti-acne agent, and optionally one or more of a skin lightening therapeutic, a sealing layer, a skin cleanser, an astringent, a skin penetration enhancer, a sunscreen, and nutritional supplements that promote healing of acne lesions. This invention also provides methods for treating acne using a vasoconstrictor in conjunction with an anti-acne agent.
... |
| Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | 20070021360 | 20070125 |
| A pharmaceutical composition and formulations comprise preventative, prophylactic or therapeutic amounts of an oligo(s) anti-sense to a specific gene(s) or its corresponding mRNA(s), and a glucocorticoid and/or non-glucocorticoid steroid or a ubiquinone or their salts. The agents, composition and formulations are used for treatment of ailments associated with impaired respiration, bronchoconstriction, lung allergy(ies) or inflammation, and abnormal levels of adenosine, adenosine receptors, sensitivity to adenosine, lung surfactant and ubiquinone, such as pulmonary fibrosis, vasoconstriction, inflammation, allergies, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction, COPD, RDS, ARDS, cancer, and others. The present treatment is effectively administered by itself for conditions without known therapies, as a substitute for therapies exhibiting undesirable side effects, or in combination with other treatments, e.g. before, during and after other... |
| Method for the normalization of sexual response and amelioration of long term genital tissue degradation | 20060281752 | 20061214 |
| The present invention provides, in one embodiment, a method of normalizing the timing of sexual response in a mammal comprising the administration of an amount of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective vasocongestive arousal. The method is applicable not only to adjusting or normalizing the timing of sexual response in humans, but in the breeding of valuable commercial animals such as horses, cattle, sheep, swine and the like and domesticated pets such as dogs and cats. In an alternative embodiment, the present invention provides a method for the prophylactic treatment of long-term tissue degradation in the genital organs comprising the administration to a mammal of a central nervous... |
| Arterial endothelial function measurement method and apparatus | 20060264755 | 20061123 |
| A “relaxoscope” (100) detects the degree of arterial endothelial function. Impairment of arterial endothelial function is an early event in atherosclerosis and correlates with the major risk factors for cardiovascular disease. An artery (115), such as the brachial artery (BA) is measured for diameter before and after several minutes of either vasoconstriction or vasorelaxafion. The change in arterial diameter is a measure of flow-mediated vasomodification (FMVM). The relaxoscope induces an artificial pulse (128) at a superficial radial artery (115) via a linear actuator (120). An ultrasonic Doppler stethoscope (130) detects this pulse 10-20 cm proximal to the point of pulse induction (125). The delay between pulse application and detection provides the pulse transit time (PTT). By measuring PTT before (160) and after arterial diameter change (170),... |
| Composition and method for treating nosebleeds | 20060252726 | 20061109 |
| A composition and method for treating nosebleed, that is, epistaxis. The composition comprises bismuth subgallate and a vasoconstriction agent, preferably oxymetazoline. The composition is preferably a paste administered intranasally.
... |
| Hypoxia induced mitogenic factor | 20060229241 | 20061012 |
| We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
... |
| Thermochromic body cavity device | 20060198423 | 20060907 |
| A body cavity device of cylindrical, spherical, annular, or tubular form with thermochromic pigments that change color in response to temperature changes. The device can be used to induce stimulation within a body cavity such as a vagina, discern the temperature within, and assess the state of vasocongestion based on correlation to temperature. The device can also be used in other applications where taking temperature measurements within the confines of an externally accessible body cavity is desired.
... |
| Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate | 20060194808 | 20060831 |
| Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL). The invention is useful for the amelioration of diabetes mellitus types 1 and 2 (including impaired glucose tolerance, pre-diabetes, insulin resistance, metabolic syndrome X and as an adjunct to oral antidiabetic agents and/or insulin), diabetic and non-diabetic microvascular diseases (including nephropathy, neuropathy and retinopathy), diabetic and non-diabetic macrovascular diseases (including heart attack, stroke, peripheral vascular disease and ischemia-reperfusion injury), hypertension, vasoconstriction, obesity, dyslipedemia, and neurodegenerative disorders (including Parkinson's disease, mild cognitive impairment, senile dementia, Alzheimer's disease,... |
| Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces | 20060172017 | 20060803 |
| Apparatus and methods deliver vasoconstrictive agents simultaneously with capnic gases. The capnic gases can enhance the effectiveness of the vasoconstrictive agent, lower the dosage of drug or concentration of agent necessary to achieve a therapeutic result, or both. Exemplary capnic gases include carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases.
... |
| Methods of increasing cerebral blood flow | 20060148702 | 20060706 |
| Methods of increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or vasospasm following hemorrhagic stroke; due to chronic high blood pressure; and/or due to idiopathic causes are provided. The method for increasing blood flow in such a mammalian brain blood vessel includes administering to a patient in need thereof a therapeutically effective amount of an inhibitor of δ protein kinase C. In certain embodiments, the inhibitor can be chronically administered without causing desensitization of the patient to the inhibitor. Kits for increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or... |
| Patient temperature regulation method and apparatus | 20060124141 | 20060615 |
| A device and method for providing body cooling. The cooling device applies cooling to blood flowing in a vena cavae that is then distributed throughout the body. The cooling can be assisted by use of thermoregulatory drugs or warming devices to prevent shivering and vasoconstriction.
... |
| Therapeutic avenanthramide compounds | 20060100274 | 20060511 |
| Methods and compositions are disclosed for reducing pro-inflammatory molecules, adhesion molecules, and vascular smooth muscle cell proliferation, and for increasing NO production. The present invention describes the use of phenolic compositions, purified from oats or synthetically produced, to decrease the effective amount of pro-inflammatory molecules and/or cell adhesion molecules. Alternatively, an alcoholic extract or concentrate from oats can be used. The methods of the present invention can be used as a treatment or prophylaxis of a wide variety of disorders associated with inflammatory states and/or with a lack of or need for nitric oxide (NO), such as inflammatory conditions, pain, free radical associated disorders, cardiovascular diseases, autoimmune disorders, pathological platelet aggregation, pathological vasoconstriction, vascular effects of diabetes, stroke, atherosclerosis, hypertension, abnormal vasospasm, and restenosis after angioplasty.
... |
